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Abstract
The DSM-5 Self-rated Level 1 Cross-Cutting Symptom Measure was developed to aid in clinical 
decision-making for clients seeking psychiatric services and to facilitate empirical investigation of 
the dimensional nature of mental health issues. Preliminary evidence supports its utility with 
clinical samples. However, the brief, yet comprehensive structure of the DSM-5 Level 1 measure 
may benefit a high-risk population that is less likely to seek treatment. College students have high 
rates of hazardous substance use and co-occurring mental health symptoms, yet rarely seek 
treatment. Therefore, the current study evaluated the psychometric properties (i.e., construct and 
criterion-related validity) of the DSM-5 Level 1 measure with a large, diverse sample of non-
treatment-seeking college/university students. Data from 7,217 college students recruited from ten 
universities in ten different states across the U.S. evidenced psychometric validation of the DSM-5 
Level 1 measure. Specifically, we found acceptable internal consistency across multi-item DSM-5 
domains and moderate to strong correlations among domains (internal validity). Further, several 
DSM-5 domains were positively associated with longer, validated measures of same mental health 
construct and had similar strengths of associations with substance use outcomes compared to 
longer measures of the same construct (convergent validity). Finally, all DSM-5 domains were 
negatively associated with self-esteem and positively associated with other theoretically relevant 
constructs, such as posttraumatic stress (criterion-related validity). Taken together, the DSM-5 
Level 1 measure appears to be a viable tool for evaluating psychopathology in college students. 
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Several opportunities for clinical application and empirical investigation of the DSM-5 Level 1 
measure are discussed.
Keywords
mental health; college students; substance use; psychometrics
Introduction
A primary goal for the recent edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5; American Psychiatric Association [APA], 2013a) was to address the 
high comorbidity and overlapping symptoms across mental health disorders (Clark & Kuhl, 
2014). The DSM-5 Self-rated Level 1 Cross-Cutting Symptom Measure (hereinafter referred 
to as DSM-5 level 1 measure; APA, 2013b) was developed in an effort to facilitate additional 
empirical investigation of the dimensional nature of mental health issues. Broadly, the 
DSM-5 level 1 measure is a brief, yet comprehensive assessment of mental health symptoms 
that are commonly endorsed among clients seeking treatment, regardless of their primary 
presenting concern (Narrow & Kuhl, 2011). Specifically, the DSM-5 level 1 measure 
comprises 23 self-rated symptoms that capture 13 mental health domains: depression, anger, 
mania, anxiety, somatic distress, suicidal ideation, psychosis, sleep disturbance, memory, 
repetitive thoughts and behaviors, dissociation, personality functioning, and substance use. 
Respondents indicate how much (or how often) they have been bothered by each symptom 
in the prior two weeks using a five-point response scale (none, not at all to severe, nearly 
every day). A score of 2 or higher in most domains, except substance use (score of 1 or 
higher) is suggestive of clinically-relevant mental health problems (Narrow et al., 2013).
Preliminary evidence for the psychometric properties of the DSM-5 level 1 measure is 
encouraging but insufficient. During the DSM-5 field trials, test-retest reliability estimates 
ranged from good to excellent for all mental health domains, except mania among clients 
recruited from seven treatment facilities across the United States (Narrow et al., 2013). 
However, Bastiaens and Galus (2017) found high rates of false positives among a sample of 
clients residing in a correctional community center, resulting in poor sensitivity and poor 
positive predictive power. Though, sensitivity of the anxiety and psychosis domains and 
negative predictive power (i.e., a negative screen) of the mania, anxiety, and psychosis 
domains were good when they used the lowest domain thresholds. The researchers 
concluded that the DSM-5 level 1 measure would benefit as a screener to rule out but not 
necessarily identify mental health issues. Although these findings are notable, the 
psychometric analyses are limited and restricted to only clinical samples (i.e., no prior 
research has evaluated the psychometric properties of the DSM-5 level 1 measure in a 
nonclinical sample). Additional psychometric validation in nonclinical samples is needed to 
determine its wider applicability.
The DSM-5 level 1 measure may be particularly useful for the college/university student 
population given the high prevalence of substance abuse, and increasing rates of mental 
health issues. More specifically, 66.7% of college students in the U.S. endorse past-month 
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alcohol use, 20.0% endorse past-month marijuana use, and roughly 30% endorse being 
diagnosed or treated by a professional for a mental health disorder (predominately 
depression and anxiety) within the past 12 months (American College Health Association, 
2017). Similar to clinical populations, college students tend to endorse symptoms that span 
several mental health disorders. Therefore, and in line with the purpose of the DSM-5 level 1 
measure, examining the breadth of potential mental health issues can facilitate the 
development of at-risk student profiles, and inform how best to address and tailor treatment 
interventions.
The goal of the present study was to evaluate the psychometric properties (i.e., construct and 
criterion-related validity) of the DSM-5 level 1 measure in a large, diverse sample of non-
treatment-seeking college/university students at 4-year institutions from ten U.S. states 
(Alaska, Colorado, Idaho, Mississippi, Missouri, Nebraska, New Mexico, Virginia, 
Washington, and Wyoming). First, we assessed internal validity of the DSM-5 level 1 
measure by examining the reliability of multiple-item mental health domains and 
intercorrelations of mental health domains. Second, we assessed convergent validity by 
examining the relation between mental health domains and longer, validated measures of the 
same mental health construct. Next, we assessed criterion-related validity by evaluating the 
association between mental health domains and theoretically-related measures of 
psychopathology. Finally, we also compared correlations between the domains and past 30-
day substance use outcomes to correlations between established measures of the same 
construct and past 30-day substance use outcomes in order determine if the DSM-5 level 1 
measure can be a viable brief measure used to assess relationships between mental health 
and substance use among college students.
Method
Participants and Procedures
Participants were college students recruited to participate in an online survey from 
Psychology Department Participant Pools at ten universities across ten U.S. states. To ensure 
that data collection was standardized at each site, all data were collected using the same 
software (i.e., Qualtrics). To minimize burden on participants, we utilized a planned missing 
data design, also known as matrix sampling (Graham, Taylor, Olchowski, & Cumsille, 
2006). Specifically, each participant received and completed a battery of core measures that 
focused on substance use (i.e., alcohol and marijuana) and the DSM-5 level 1 measure. After 
completing the core measures, each participant received a random sample of 10 measures 
from a larger pool (19 total measures) that assessed mental health (e.g., depression, anxiety, 
stress, self-esteem, suicide, posttraumatic stress), physical health (i.e. sleep quality, sexual 
experiences, eating habits), and personality (i.e., impulsivity-like traits, Big Five personality 
traits, antisocial behavior, and temperament) constructs. Although 7,307 students were 
recruited across sites, only data from students that completed the DSM-5 level 1 measure (n 
= 7,217) were included in the final analyses. The majority of the analytic sample was White 
(73.80%), female (70.54%), and reported a mean age of 20.85 (Median = 19.00; SD = 4.74) 
years. Specific demographic information on our full sample as well as each data collection 
site is shown in Supplemental Table 1. Participants received research participation credit for 
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completing the study. This protocol was approved by the institutional review boards at each 
participating university.
Non-DSM Level 1 Measures
Based on our missing-data-by-design procedure, at least 3,746 (51.91%) of participants 
completed each randomized measure unless otherwise noted.
Depression, anxiety, and stress.—Past week depression, anxiety, and stress were 
assessed using the 21-item Depression Anxiety Stress Scales (DASS-21; Lovibond & 
Lovibond, 1995) measured on a 4-point response scale (0 = did not apply to me at all to 3 = 
applied to me very much, or most of the time). We summed items to create a total score for 
the three domains covered by the measure: depression (7 items; M = 3.42; SD = 4.48; α = .
92), anxiety (7 items; M = 3.15; SD = 3.86; α = .86), and stress (7 items; M = 4.18; SD = 
4.24; α = .88).
Fear of Negative Evaluation.—Fear of negative evaluation was assessed using the 12-
item Brief Fear of Negative Evaluation Scale (BFNES; Leary, 1983), measured on a 5-point 
response scale (1 = not at all characteristic of me to 5 = extremely characteristic of me). 
Items were summed (M = 33.88; SD = 9.92; α = .89).
Social Interaction Anxiety.—Social interaction anxiety was assessed using the 20-item 
Social Interaction Anxiety Scale (SIAS; Mattick & Clarke, 1998), measured on a 5-point 
response scale (0 = not at all characteristic or true of me to 4 = extremely characteristic or 
true of me). Items were summed (M = 26.24; SD = 15.81; α = .94).
Posttraumatic stress disorder.—Past month posttraumatic stress disorder (PTSD) 
symptoms was assessed using the 20-item PTSD Checklist for DSM-5 (PCL-5; Blevins, 
Weathers, Davis, Witte, & Domino, 2015), measured on a 5-point response scale (0 = not at 
all to 4 = extremely). Items were summed (M = 16.00; SD = 16.67; α = .96).
Insomnia.—Past 2-week insomnia problems was assessed using the 7-item Insomnia 
Severity Index (ISI; Bastien, Vallières, & Morin, 2001), measured on a 5-point response 
scale (0 = not at all to 4 = extremely). The seven items assess severity of difficulties falling 
asleep, staying asleep, sleep quality and its impact on daily functioning. We summed items 
to create a total score of insomnia (M = 7.86; SD = 5.75; α = .88).
Suicidality.—Suicidality was assessed with three independent questions adapted from the 
World Mental Health Composite International Diagnostic Interview (CIDI; Kessler & Üstün, 
2004). The three questions focused on suicidal thought (“Did you think about killing 
yourself?”), planning a suicide (“Did you make a plan to kill yourself?”), and suicide 
attempts (“Did you make a suicide attempt or try to kill yourself?”). Participants reported 
whether they did or did not (0 = no, 1 = yes) experience suicidal thoughts (16.01% endorsed 
yes), plan to kill themselves (3.85% endorsed yes), and attempt suicide (1.89% endorsed 
yes) in the past 12 months.
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Self-esteem.—Self-esteem was assessed using the 10-item Rosenberg Self-Esteem Scale 
(Rosenberg, 1965), measured on a 5-point response scale (0 = strongly agree to 4 = strongly 
disagree). We reverse-coded and summed items to create a total score with higher scores 
indicating higher positive self-esteem (M = 20.27; SD = 5.86; α = .90).
Alcohol use.—Alcohol use was broken down into several indicators: an indicator of past 
30-day frequency of alcohol use, an indicator of typical quantity, and an indicator of binge 
drinking frequency (i.e., past 30-day frequency of drinking 4+/5+ standard drinks in for 
women/men in a period of two hours or less). Typical quantity was measured with a 
modified version of the Daily Drinking Questionnaire (Collins, Parks, & Marlatt, 1985). 
Participants indicated how much they drink during a typical week in the past 30 days using a 
7-day grid from Monday to Sunday. We summed number of standard drinks consumed on 
each day of the typical drinking week (i.e., “weekly drinks”). Only participants that reported 
at least one alcohol use day in the previous month (n = 5,001) completed the binge drinking 
frequency and typical quantity questions.
Alcohol-related problems.—Past 30-day alcohol-related problems were assessed using 
the 24-item Brief-Young Adult Alcohol Consequences Questionnaire (Kahler, Strong, & 
Read, 2005). Each item was scored dichotomously (0 = no, 1 = yes) and we summed all 
items to create an alcohol-related problem composite score reflective of the number of 
distinct problems experienced in the past 30 days (α = .91). Only participants that reported 
at least one alcohol use day in the previous month (n = 5,001) completed the measure.
Alcohol misuse.—Alcohol misuse was assessed using a modified version of the 10-item 
Alcohol Use Disorder Identification Test (AUDIT; Saunders, Aasland, Babor, de la Fuente, 
& Grant, 1993). The difference between the AUDIT and the modified version is that the 
response options for items 1–3 were modified and the wording for item 3 reflects the U.S. 
gender-specific definition of heavy episodic drinking (i.e., frequency of drinking 4+/5+ 
standard drinks in for women/men in a drinking period). We summed items to create a total 
score for the two primary domains covered by the measure: alcohol consumption (3 items; 
M = 5.71; SD = 3.60; α = .82) and alcohol-related problems (7 items; M = 2.42; SD = 3.55; 
α = .78). Only participants that reported consuming alcohol at least once in their lifetime (n 
= 6,366) completed the measure.
Marijuana use.—Marijuana use was broken down into several indicators: an indicator of 
past 30-day marijuana use, an indicator of typical frequency of use, and an indicator of 
typical quantity. Typical marijuana use frequency and quantity was assessed using the 
Marijuana Use Grid (Author et al., 2018). Specifically, each day of the week was broken 
down into 6 4-hour blocks of time (12a-4a, 4a-8a, 8a-12p, etc.), and participants were asked 
to report at which times they used marijuana during a “typical week” in the past 30 days as 
well as the quantity of grams consumed during that time block. We calculated typical 
frequency of marijuana use by summing the total number of time blocks for which they 
reported using during the typical week (ranges: 0–42). We calculated typical quantity of 
marijuana use by summing the total number of grams consumed across time blocks during 
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the typical week. Only participants that reported at least one marijuana use day in the 
previous month (n = 2,175) completed the marijuana use frequency and quantity questions.
Marijuana-related problems.—Past 30-day marijuana-related problems were assessed 
using the 21-item Brief Marijuana Consequences Questionnaire (Simons, Dvorak, Merrill, & 
Read, 2012). Each item was scored dichotomously (0 = no, 1 = yes) and we summed all 
items to create a marijuana-related problems composite score reflective of the number of 
distinct problems experienced in the past 30 days (α = .89). Only participants that reported 
at least one marijuana use day in the previous month (n = 2,175) completed the measure.
Marijuana misuse.—Marijuana misuse was assessed using the 8-item Cannabis Use 
Disorders Identification Test-Revised (CUDIT-R; Adamson et al., 2010). We summed items 
to create a total score with higher scores indicating higher marijuana misuse (M = 5.57; SD 
= 5.82; α = .84). Only participants that reported consuming marijuana at least once in their 
lifetime (n = 4,018) completed the measure.
Statistical Analyses
To test for internal validity, we examined the reliability of test scores from domains that had 
multiple items and correlations between domains. To test for convergent validity (i.e., 
evidence of a relationship between the test scores and other scores from measures of the 
same or similar construct), we examined the correlations between five specific domains and 
other measures purported to assess the same (or similar) construct: 1) the depression domain 
with the DASS-21 depression subscale; 2) the anxiety domain with the DASS-21 anxiety 
subscale and two forms of social anxiety (fear of negative evaluation and social interaction 
anxiety); 3) the suicidal ideation domain and three forms of suicidality (i.e., thoughts, 
planning, and attempt); 4) the sleep disturbance domain with insomnia, and 5) the substance 
use domain with reports on the AUDIT, CUDIT-R, and past 30-day alcohol and marijuana 
use/problems. To test for criterion-related validity (i.e., the relationship between the test’s 
scores with other theoretically relevant constructs), we examined the correlations between 
the 13 domains and all mental health constructs mentioned in the measures section that were 
not the exact same construct (e.g., correlation between depression and PTSD symptoms).
Furthermore, we compared correlations between these domains and past 30-day substance 
use outcomes to correlations between established measures of the same construct and past 
30-day substance use outcomes in order determine if the DSM-5 level 1 measure can be a 
viable brief measure used to assess relationships between mental health and substance use. 
Since we utilized a missing-data-by-design procedure, missing data are considered missing 
completely at random or MCAR (Enders, 2010), which allows us to use Full Information 
Maximum Likelihood in Mplus 7.4 to handle missing data (i.e., allows us to use all available 
information in determining parameter estimates) (Muthén & Muthén, 1998–2017). Given 
our large sample size (i.e., statistical power), significant associations were determined by a 
99% bias-corrected standardized bootstrapped confidence interval (based on 10,000 
bootstrapped samples) that does not contain zero and we place emphasis on the strength of 
the associations.
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Internal Validity and Descriptive Statistics
Of the 13 domains assessed by the DSM-5 level 1 measure, eight had multiple items and 
each of these domains had acceptable to good internal consistency (Loewenthal, 2001) 
within this college student population: depression (2 items; M = 2.00; SD = 2.01; α = .82), 
anger (1 item; M = .99; SD = 1.05), mania (2 items; M = 1.52; SD = 1.74; α = .63), anxiety 
(3 items; M = 2.90; SD = 2.96; α = .84), somatic distress (2 items; M = 1.21; SD = 1.76; α 
= .70), suicidal ideation (1 item; M = 0.28; SD = 0.74), psychosis (2 items; M = 0.29; SD = .
96; α = .80), sleep disturbance (1 item; M = .89; SD = 1.18), memory (1 item; M = .46; SD 
= .87), repetitive thoughts and behaviors (2 items; M = .79; SD = 1.52; α = .75), dissociation 
(1 item; M = .44; SD = .89), personality functioning (2 items; M = 1.48; SD = 1.98; α = .
81), and substance use (3 items; M = 1.06; SD = 1.81; α = .61). As expected, all domains 
were significantly positively associated with each other and the majority of these magnitudes 
were in the moderate (.30 < rs < .50) to strong range (r > .50).
Beyond examining mean rates and correlations among domains, we also calculated 
prevalence rates (i.e., percentages) of participants who met the threshold for 
psychopathology symptom criteria. Within the total sample and averaged across items, the 
prevalence of potential symptom presentation for the domains are as follows: anxiety 
(27.89%), depression (27.87%), anger (27.54%), sleep disturbance (25.47%), mania 
(21.91%), personality functioning (20.07%), somatic distress (17.11%), memory (12.09%), 
dissociation (11.70%), repetitive thoughts and behaviors (10.95%), suicidal ideation 
(7.46%), and psychosis (4.00%). For substance use, we present the rates by specific 
substance: alcohol use (32.06%), tobacco (15.53%), and other drug use (14.68%). Specific 
percentage rates for each item in our full sample (and across data collection sites) is shown 
in Supplemental Table 2. Specific percentage rates for each item across racial/ethnic 
identities are shown in Supplemental Table 3. We also compared our sample to a community 
sample obtained by Hurst and Kavanagh (2017). By and large, our sample demonstrated 
lower rates on most mental health domains except for slightly higher prevalence of tobacco 
use and prescription drug misuse (see Supplemental Table 2).
Convergent and Criterion-related Validity
Correlations between domains of the DSM-5 level 1 measure and mental health constructs 
are summarized in Table 1. Across all domain specific correlations, all correlations were 
significantly positive and the majority of these magnitudes were in the moderate to strong 
range: 1) depression domain with the DASS-21 depression subscale (r = .67); 2) sleep 
disturbance domain with insomnia (r = .66); 3) anxiety domain with fear of negative 
evaluation (r = .42), social interaction anxiety (r = .48), and the DASS-21 anxiety subscale (r 
= .58); 4) suicidal ideation domain with past year suicidality thoughts (r = .48), planning (r 
= .39), and attempt (r = .23); 5) substance use domain with reports on the AUDIT 
(consumption, r = .45; problems, r = .45), CUDIT-R (r = .37), and past 30-day alcohol/
marijuana use indicators and related problems (rs = .19-.41). With regards to criterion-
related validity, all domains of the DSM-5 level 1 measure were significantly positively 
associated with each poor mental health construct (only exception was alcohol consumption 
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assessed by the AUDIT; only four significant associations). The majority of these 
magnitudes ranged from moderate-to-strong (see Table 1).
Correlations between health constructs and past 30-day substance use outcomes are 
summarized in Table 2. Excluding the substance use domain of the DSM-5 level 1 measure, 
there were relatively few significant associations between mental health constructs and both 
alcohol and marijuana use indicators and all significant correlations were weak. In contrast, 
almost all correlations between mental health constructs and alcohol/marijuana-related 
problems were significant and had modest associations (correlations ranged from .15 to .31). 
In comparing the associations between the five specific domains and other measures 
assessing the same (or similar) construct on substance use outcomes, the correlations were 
largely similar in strength (e.g., the correlation between the depression domain and 
marijuana-related problems was .21 and the correlation between DASS-21 depression and 
marijuana-related problems was .21). Other correlation comparisons were similar in strength 
(i.e., .10 or less in magnitude difference).
Discussion
Broadly, the present study sought to test the utility of the DSM-5 level 1 measure in 
assessing psychopathology among college students through a systematic testing of internal, 
convergent, and criterion-related validity. Overall, the measure performed admirably. All 
multi-item subscales of the DSM-5 level 1 measure demonstrated at least acceptable internal 
consistency estimates and were moderately-to-strongly correlated with each other (internal 
validity). Further, several domains were strongly, positively associated longer measures of 
the same (or similar) constructs and the associations between mental health symptoms and 
substance use outcomes were remarkably similar across the brief DSM-5 level 1 measure 
mental health domains and the longer, more validated measures assessing these constructs 
(convergent validity). Not only were the 13 domain measures negatively associated with 
self-esteem, but they tended to correlate strongly with other theoretically-relevant constructs 
such as posttraumatic stress (criterion-related validity). Taken together, our findings further 
support the utility of this measure in non-clinical samples (Hurst & Kavanagh, 2017).
Specific to the present study, our findings provide evidence that the DSM-5 level 1 measure 
could have incredible value as a brief, comprehensive measure of mental health among 
college students. Given its brevity, we anticipate that a growing number of researchers will 
strategically use the DSM-5 level 1 measure in college student populations. As the first 
study using this measure in this population, we have provided detailed information about 
prevalence rates in our total sample and both site-specific and racial/ethnic subsamples to 
facilitate comparisons in future studies. Although the present study relied on convenience 
sampling, which limits our contributions from an epidemiological perspective, we provide a 
strong reference point to which other studies using the DSM-5 level 1 measure can be 
compared. Moreover, and with particular attention to the high rates of substance use among 
college students, brief motivational interventions may also benefit from using the DSM-5 
level 1 measure to gain a fuller picture of the mental health issues associated with college 
student substance use. In fact, incorporating the DSM-5 level 1 measure into such 
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interventions can help guide conversations surrounding the facilitative and detrimental 
effects of substance use.
Limitations and Future Directions
Despite the importance of these findings, our study was not without its limitations. The 
cross-sectional study design prevents the examination and demonstration of temporal 
precedence. Furthermore, the present study did not collect clinical diagnosis data to 
determine if the proposed cutoffs by Narrow and colleagues (2013) are valid for the college 
population. Additional work is needed to examine the sensitivity and specificity of the 
DSM-5 level 1 to inform its utility as a mental health screener among college students. 
Moreover, further validation of the DSM-5 level 1 measure will increase confidence in 
current findings, as well as facilitate epidemiological research on the prevalence, incidence, 
and impact of psychopathology among college students and aid in developing profiles for at-
risk student.
Although we had multiple mental health measures resulting in our ability to compare the 
DSM-5 level 1 measure estimates of specific psychopathology to more comprehensive 
measures of overlapping constructs, we did not compare the measure to larger, 
comprehensive measures of overall psychopathology (e.g., Counseling Center Assessment 
of Psychological Symptoms-62; Locke et al., 2011). These comparisons are needed to 
determine whether researchers can use the measure to evaluate the myriad of psychiatric 
issues commonly experienced by college students without placing undue burden on them 
through extensive psychological evaluation. Finally, the DSM-5 Level 1 measure currently 
does not have normative data and has not been evaluated according to the Standards for 
Educational and Psychological Testing which is needed to provide greater empirical 
validation of the measure (see Al-Dajani, Gralnick, & Bagby, 2015 for an example of testing 
a DSM-5 measure using these standards).
Conclusions
The current study provides psychometric validation of the DSM-5 Self-Rated Level 1 Cross-
Cutting Symptoms Measure with a large, diverse sample of non-treatment-seeking college 
students. The high prevalence of hazardous substance use and increasing rates of mental 
health issues among college students points to the DSM-5 level 1 measure as a viable tool to 
identify and address the needs of this population. Further, the tool may prove useful for 
empirical investigations of the profiles of at-risk students while minimizing relative 
participant burden. Although additional validation of the DSM-5 level 1 measure with the 
college student population is needed, we foresee opportunities to augment epidemiological 
research, theoretical conceptualizations, and clinical applications using the DSM-5 level 1 
measure with the college student population.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Empirical investigations surrounding the etiology and pathophysiology of mental health 
issues in college students may benefit from a brief, yet comprehensive measure of mental 
health issues. This study supports the notion that the DSM-5 Self-rated Level 1 Cross-
Cutting Symptom Measure is a viable tool for identifying and addressing the needs of 
this population.
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